02 Oct2015
PeptiDream, Teijin to co-discover peptide-based therapeutics
The agreement indicates that PeptiDream will use its proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Teijin
Tokyo: PeptiDream Inc., a Tokyo-based biopharmaceutical company, has signed a multi-target discovery and optimization collaboration agreement with Teijin Pharma Limited, Tokyo, Japan.
